Literature DB >> 30427104

Histopathological characterization of the neuroglial tissue in ovarian teratoma associated with anti-N-methyl-D-aspartate (NMDA) receptor encephalitis.

Yoshiki Iemura1, Yosuke Yamada1, Masahiro Hirata1, Tatsuki R Kataoka1, Sachiko Minamiguchi1, Hinonori Haga1.   

Abstract

Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is a rare but occasionally fatal limbic encephalitis that may be accompanied by ovarian teratoma. Since the neuroglial tissue within the teratoma may be involved in the pathogenesis of this encephalitis, we attempted morphological and immunohistochemical characterization of the neuroglial tissue in four cases of ovarian teratoma associated with anti-NMDA receptor encephalitis and 12 control cases, i.e., six consecutive cases of immature teratoma and six cases of mature teratoma with an abundant neuronal component, focusing mainly on NMDA receptor-expressing neurons. NMDA receptor-expressing neurons, being observed in all of the cases analyzed, were significantly densely aggregated (P = 0.030, Wilcoxon test) and relatively smaller in size in the encephalitis-associated cases than in the control cases, and the Ki-67 labeling index of neuroglial cells with these neurons was significantly higher in the encephalitis-associated cases (P = 0.004, Wilcoxon test). In the cases with encephalitis, aggregation of B-cells within or around the neuroglial tissue was also observed. Our present findings may be useful for more accurate diagnosis of anti-NMDA receptor encephalitis and contribute to a better understanding of the pathogenesis.
© 2018 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  N-methyl-D-aspartate receptors; anti-N-methyl-D-aspartate receptor encephalitis; histology; neurons; ovary; teratoma

Mesh:

Year:  2018        PMID: 30427104     DOI: 10.1111/pin.12732

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  6 in total

Review 1.  Anti-NMDA Receptor Encephalitis: Retrospective Analysis of 15 Cases, Literature Review, and Implications for Gynecologists.

Authors:  Yibin Liu; Yanpeng Tian; Ruoyi Guo; Xin Xu; Mingle Zhang; Zhongkang Li; Yanlai Xiao; Wen Cao; He Gao; Desheng Kong; Yanfang Du; Li Meng; Jingkun Zhang; Xianghua Huang
Journal:  J Healthc Eng       Date:  2022-03-15       Impact factor: 2.682

Review 2.  Ovarian Teratoma-Related Paraneoplastic Neurological Syndromes.

Authors:  Jingfang Lin; Minjin Wang; Jierui Wang; Jinmei Li
Journal:  Front Oncol       Date:  2022-05-16       Impact factor: 5.738

Review 3.  Ovarian and non-ovarian teratomas: a wide spectrum of features.

Authors:  Tsukasa Saida; Kensaku Mori; Tomohiko Masumoto; Sodai Hoshiai; Toshitaka Ishiguro; Masafumi Sakai; Tadashi Hara; Hiroyuki Ochi; Toyomi Satoh; Manabu Minami
Journal:  Jpn J Radiol       Date:  2020-09-01       Impact factor: 2.374

4.  Immunopathological characterization of ovarian teratomas associated with anti-N-methyl-D-aspartate receptor encephalitis.

Authors:  Aude Chefdeville; Isabelle Treilleux; Marie-Eve Mayeur; Coline Couillault; Géraldine Picard; Chloé Bost; Karima Mokhtari; Alexandre Vasiljevic; David Meyronet; Véronique Rogemond; Dimitri Psimaras; Bertrand Dubois; Jérôme Honnorat; Virginie Desestret
Journal:  Acta Neuropathol Commun       Date:  2019-03-11       Impact factor: 7.801

Review 5.  The Association of Ovarian Teratoma and Anti-N-Methyl-D-Aspartate Receptor Encephalitis: An Updated Integrative Review.

Authors:  Cheng-Yang Wu; Jiann-Der Wu; Chien-Chin Chen
Journal:  Int J Mol Sci       Date:  2021-10-09       Impact factor: 5.923

6.  Co-expression of NMDA-receptor subunits NR1, NR2A, and NR2B in dysplastic neurons of teratomas in patients with paraneoplastic NMDA-receptor-encephalitis: a retrospective clinico-pathology study of 159 patients.

Authors:  Xin-Yue Jiang; Song Lei; Le Zhang; Xu Liu; Min-Tao Lin; Ingmar Blumcke; Yue-Shan Piao; Dong Zhou; Jin-Mei Li
Journal:  Acta Neuropathol Commun       Date:  2020-08-08       Impact factor: 7.801

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.